JP2013505205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505205A5 JP2013505205A5 JP2012529137A JP2012529137A JP2013505205A5 JP 2013505205 A5 JP2013505205 A5 JP 2013505205A5 JP 2012529137 A JP2012529137 A JP 2012529137A JP 2012529137 A JP2012529137 A JP 2012529137A JP 2013505205 A5 JP2013505205 A5 JP 2013505205A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- epratuzumab
- administered
- composition according
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24379709P | 2009-09-18 | 2009-09-18 | |
| US61/243,797 | 2009-09-18 | ||
| PCT/EP2010/005225 WO2011032633A1 (en) | 2009-09-18 | 2010-08-26 | Treatment of autoimmune and inflammatory diseases with epratuzumab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013505205A JP2013505205A (ja) | 2013-02-14 |
| JP2013505205A5 true JP2013505205A5 (https=) | 2013-09-26 |
| JP5816905B2 JP5816905B2 (ja) | 2015-11-18 |
Family
ID=43063209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529137A Expired - Fee Related JP5816905B2 (ja) | 2009-09-18 | 2010-08-26 | エプラツズマブを用いる自己免疫疾患及び炎症性疾患の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110070227A1 (https=) |
| EP (1) | EP2478012B1 (https=) |
| JP (1) | JP5816905B2 (https=) |
| KR (1) | KR20120100914A (https=) |
| CN (1) | CN102574920A (https=) |
| AU (1) | AU2010294905B2 (https=) |
| BR (1) | BR112012006035A2 (https=) |
| CA (1) | CA2774244A1 (https=) |
| EA (1) | EA026902B1 (https=) |
| ES (1) | ES2608661T3 (https=) |
| IN (1) | IN2012DN02196A (https=) |
| MX (1) | MX341117B (https=) |
| WO (1) | WO2011032633A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| RU2553225C2 (ru) | 2008-05-23 | 2015-06-10 | Сива Корпорейшн | Способ облегчения регенерации |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| US9757458B2 (en) * | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| JP6392765B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| EP3194439B1 (en) * | 2014-09-19 | 2022-01-19 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| HUE058854T2 (hu) | 2016-02-19 | 2022-09-28 | Siwa Corp | Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával |
| KR20180133452A (ko) | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
| JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| PT3528787T (pt) | 2016-10-21 | 2026-03-11 | Amgen Inc | Formulações farmacêuticas e métodos para produzir as mesmas |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| CA3059803A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CA3064804A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| KR102270107B1 (ko) | 2017-08-18 | 2021-06-30 | 메디뮨 리미티드 | 피롤로벤조디아제핀 컨쥬게이트 |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3867280A4 (en) * | 2018-10-18 | 2022-11-09 | Sinomab Bioscience Limited | METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| DE69534530T2 (de) * | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| BRPI0315295C1 (pt) * | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| EP1999148B8 (en) * | 2006-03-06 | 2014-03-05 | Medlmmune, LLC | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| CN101490087B (zh) * | 2006-05-30 | 2013-11-06 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
| US8283162B2 (en) * | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
-
2010
- 2010-08-25 US US12/868,338 patent/US20110070227A1/en not_active Abandoned
- 2010-08-26 MX MX2012002907A patent/MX341117B/es active IP Right Grant
- 2010-08-26 CN CN2010800412158A patent/CN102574920A/zh active Pending
- 2010-08-26 KR KR1020127009393A patent/KR20120100914A/ko not_active Ceased
- 2010-08-26 EA EA201270433A patent/EA026902B1/ru not_active IP Right Cessation
- 2010-08-26 CA CA2774244A patent/CA2774244A1/en not_active Abandoned
- 2010-08-26 ES ES10751563.7T patent/ES2608661T3/es active Active
- 2010-08-26 BR BR112012006035A patent/BR112012006035A2/pt not_active IP Right Cessation
- 2010-08-26 WO PCT/EP2010/005225 patent/WO2011032633A1/en not_active Ceased
- 2010-08-26 AU AU2010294905A patent/AU2010294905B2/en not_active Ceased
- 2010-08-26 IN IN2196DEN2012 patent/IN2012DN02196A/en unknown
- 2010-08-26 JP JP2012529137A patent/JP5816905B2/ja not_active Expired - Fee Related
- 2010-08-26 EP EP10751563.7A patent/EP2478012B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505205A5 (https=) | ||
| JP2015515475A5 (https=) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2012193216A5 (https=) | ||
| JP2006504795A5 (https=) | ||
| JP2018193377A5 (https=) | ||
| JP2016518387A5 (https=) | ||
| JP2016512248A5 (https=) | ||
| JP2013542247A5 (https=) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| JP2009525343A5 (https=) | ||
| JP2012515184A5 (https=) | ||
| JP2012502909A5 (https=) | ||
| WO2007012022A3 (en) | Unit dose form with ibuprofen-famotidine admixture | |
| NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| JP2012533565A5 (https=) | ||
| RU2009142937A (ru) | Тапентадол для лечения в связи с остеоартрозом | |
| JP2015537009A5 (https=) | ||
| RU2016103764A (ru) | Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан | |
| WO2015009731A3 (en) | Azacyclic constrained analogs of fty720 | |
| RU2013157398A (ru) | Композиция | |
| JP2011500589A5 (https=) | ||
| JP2013540734A5 (https=) | ||
| IL300144A (en) | Benzazepines are combined for the treatment of Tourette syndrome | |
| JP2014510780A5 (https=) |